Search results for: Downs
As Retina Innovators Look Outside US for Funding, Here’s What to Watch Out For
CHICAGO – As innovation in the retina space has grown over the past quarter century, so has the need for capital to finance those activities. One way innovators are meeting that need is by entering into partnerships with ex-US entities, one of many issues explored by a panel session on financing retina innovation at OIS@ASRS…
Read MoreWhy Link Between Cognition and Vision May Emerge as a Focus of Innovation
WASHINGTON – With the graying of America and a push to create age-friendly communities and health systems, ophthalmologists and innovators in the field need to better understand the interplay between low vision and cognition for the best outcomes, a panel of experts said at Prevent Blindness’ 2019 Focus on Eye Health summit. The number of…
Read MoreOIS Index Delivers Stellar First-Quarter 2019 Performance
The OIS Index of ophthalmic stocks solidly outperformed its market benchmarks in the first quarter of 2019, gaining 37.1%. During Q1, the overall US stock market, as measured by the Russell 3000 Index, gained 12.8%. The NASDAQ Biotechnology Index gained 15.4%, and a composite of US medical device stocks gained 15.9%. For the OIS Index,…
Read MoreHow Newer Diagnostics and Devices Are Making Dry Eye Treatments an Easier Sell
WASHINGTON, DC – Treating flairs and fluctuations while employing steroid tapering for the treatment of dry eye was the hot topic during the dry eye panel at OIS@ASCRS 2018. The consensus from panelists Sam Garg, MD (Gavin Herbert Eye Institute), Preeya Gupta, MD (Duke University Eye Center), and John Sheppard, MD (Virginia Eye Consultants) was…
Read MoreOhr Set to Begin Phase III Trials for Wet AMD
Jason Slakter, CEO, Ohr Pharmaceutical, told OIS@AAO attendees that the company is enrolling patients in a Phase III clinical trial to test the efficacy of its topical Squalamine Lactate Ophthalmic Solution, which is used in combination with anti-VEGF agents to treat wet age-related macular degeneration (AMD). The clinical endpoint of the trial is vision gain…
Read MoreAerpio’s Unique Approach to Activating Tie2
Joseph Gardner, president and CEO of Aerpio Therapeutics, acknowledged that his company is not alone in developing Tie2-activating agents to treat retinal disease, but at OIS@AAO 2016 he laid out the case for why his company’s programs should be taken seriously in the space. Aerpio has two first-in-class products for treating retinopathies, both focused on…
Read MoreOIS@ASRS Co-Chair Mark Humayan Says Attention to Retina “Long Overdue”
New ASRS President Mark S. Humayun, MD, PhD, shares the challenges of entrepreneurship in innovation. Co-Inventor of the world’s first FDA approved artificial retinal prosthesis developed by Second Sight, Humayan tells OIS-TV the device side “is under a lot of pressure … I really hope that trend doesn’t go too far to the right and…
Read MoreIntroducing Our Newest Tool – The OIS Index
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 106″] OIS has partnered with Michael Lachman of EyeQ Research to create a vital new stock index of ophthalmology companies. This new tool will enable us to deliver broader insights and stronger analysis of our exciting sector. Podcast Guest: Michael Lachman Michael Lachman is President of EyeQ Research, which provides market…
Read MoreAerie’s Positive Data Keep Wall Street Happy
Earlier this month, Aerie Pharmaceuticals filed its first NDA for once-daily Rhopressa (netarsudil) and released top-line data from its once-daily Roclatan (Rhopressa and latanoprost) Mercury 1 study; both of Aerie’s products are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. With Roclatan meeting its primary efficacy endpoint in each…
Read MoreApellis Eyeing 2017 Release of Phase II Results
Cedric Francois, CEO, Apellis Pharmaceuticals, hopes to deliver positive results to the company’s Phase II clinical trials of APL-2, a peptide targeting the C3 inhibitor in the complement cascade as a treatment for geographic atrophy (GA). The company has fully enrolled the Filly trial of APL-2. (APL-1 is targeting COPD.) The 240 patients in the…
Read MoreTMi Raising Money to Convert Destructive Macrophage
Shelley Boyd, MD, president and CSO, Translatum Medicus Inc. (TMi), reports the company has started raising capital to initiate preclinical studies – and possibly Phase II clinical trials – of TMI-018, a drug candidate that might convert potentially destructive macrophages. The company is building a case that aggressive M1 macrophages are the cause of retinal…
Read MoreFunding Companies in Today’s Volatile Market
US financial markets had “the worst 10-day start for Wall Street in history” in January 2016, said Andrew Gitkin, managing director and head of West Coast biotechnology investment banking at Piper Jaffray, but by February/March markets had bounced back a bit. What the market is now experiencing is a “flight to safety in US-dominated assets.…
Read More